Agenus (AGEN) vs C4 Therapeutics (CCCC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Agenus (AGEN) has outperformed C4 Therapeutics (CCCC) over the past year, gaining 78.1% versus a gain of 24.8%. Over five years, AGEN leads with a -92.7% price change compared with -93.6% for CCCC. C4 Therapeutics is the larger company by market cap ($346.9 million vs $341.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AGEN | CCCC |
|---|---|---|
| Share price | $7.57 | $2.82 |
| Market cap | $341.88M | $346.93M |
| 1-day change | +1.07% | -2.08% |
| YTD return | +141.08% | +47.64% |
| 1-year return | +78.12% | +24.78% |
| 5-year return | -92.74% | -93.57% |
| P/E ratio (TTM) | 2.99 | — |
| EPS (TTM) | $2.53 | $-0.91 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $10.31 | $5.17 |
| 52-week low | $2.71 | $1.69 |
| Distance from 52-week high | -26.58% | -45.45% |
| Analyst consensus | strong_buy | strong_buy |
| Avg. price target upside | +247.82% | +372.70% |
| Average volume | 4.25M | 2.39M |
| Shares outstanding | 45.16M | 123.03M |
| Employees | 81 | 104 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AGEN has outperformed CCCC by 53.3 percentage points over the past year.
About Agenus
AGEN stock →Agenus Inc., a clinical-stage biotechnology company, discovers and develops immunotherapies for cancer and infectious diseases in the United States and internationally. It offers Retrocyte Display, an antibody expression platform for the identification of fully human and humanized monoclonal antibodies; and display technologies.
Healthcare · Biotechnology · 81 employees
About C4 Therapeutics
CCCC stock →C4 Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops novel therapeutic candidates to degrade disease-causing proteins. Its lead product candidate is Cemsidomide, an orally bioavailable monodac targeting IKZF1 and IKZF3, or IKZF1/3 to address a need across multiple lines of therapy in multiple myeloma, which has competed its phase 1.
Healthcare · Biotechnology · 104 employees
AGEN vs CCCC FAQ
Which is bigger, Agenus or C4 Therapeutics?
C4 Therapeutics (CCCC) is larger, with a market capitalization of $346.93M compared with $341.88M for Agenus (AGEN).
Which stock has performed better over the past year, AGEN or CCCC?
AGEN returned +78.12% over the past 12 months, compared with +24.78% for CCCC (price return, excluding dividends). Past performance does not predict future results.
Are Agenus and C4 Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.